TGRX-1942

· Shenzhen TargetRx Co., Ltd.

Drug timelines are a Plus or Pro feature.

1 regulatory and trial event tracked for TGRX-1942, covering 2025-02-24 to 2025-02-24. Get the full timeline:

Most recent: Clinical Trial Update: TGRX-1942 Chinese Phase I for Advanced Solid Tumor And/or Relapsed/Refractory Hematologic Malignancies [Phase 1]